Designed for regulated cell therapy translation
A quality-by-design mindset spanning manufacturing philosophy, critical quality attributes, ecosystem capacity, and inspection-readiness.
Manufacturing philosophy.
Built around the attributes regulators expect.
Brazilian advanced therapy infrastructure access.
BioNK’s development strategy is supported by access to Brazilian advanced therapy manufacturing, cryopreservation and logistics capabilities through the Cryopraxis ecosystem, subject to applicable quality agreements, regulatory requirements and project-specific validation.
Specific process qualifications are determined on a project-by-project basis and are not represented as universally validated.
A standardized translation flow.
Audit-ready by design.
Document control, deviation management, CAPA, batch records, audit readiness, chain of custody and data integrity are foundational to how BioNK approaches manufacturing maturation — from research through clinical material supply.